Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

12.50
-0.5600-4.29%
Post-market: 12.500.00000.00%17:20 EDT
Volume:843.54K
Turnover:10.67M
Market Cap:1.04B
PE:-3.94
High:13.12
Open:12.95
Low:12.44
Close:13.06
52wk High:19.11
52wk Low:3.91
Shares:83.43M
Float Shares:59.91M
Volume Ratio:1.01
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1700
EPS(LYR):-3.1667
ROE:-72.19%
ROA:-38.89%
PB:3.41
PE(LYR):-3.95

Loading ...

EyePoint doses first patients in Phase 3 DURAVYU trials for diabetic macular edema

Reuters
·
Mar 02

EyePoint Inc: Topline Data for Duravyu in Dme Anticipated in 2H 2027

THOMSON REUTERS
·
Mar 02

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of Duravyu™ for the Treatment of Diabetic Macular Edema

THOMSON REUTERS
·
Mar 02

EyePoint Inc. to Report Fourth-Quarter and Full-Year Financial Results on Conference Call

Reuters
·
Feb 25

EyePoint management to participate in upcoming investor conferences

Reuters
·
Feb 24

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

TIPRANKS
·
Feb 24

EyePoint Chief Medical Officer Ramiro Ribeiro Disposes of Common Shares

Reuters
·
Feb 19

EyePoint Names Michael Campbell Chief Commercial Officer

Reuters
·
Feb 18

EyePoint Appoints Michael Campbell as Chief Commercial Officer

THOMSON REUTERS
·
Feb 18

BRIEF-Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Feb 17

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Feb 17

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 17

EyePoint Inc. nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Reuters
·
Feb 05

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Jan 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 16

EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target

TIPRANKS
·
Jan 08

EyePoint Inc. Chief Medical Officer Ramiro Ribeiro Reports Disposal of Common Shares

Reuters
·
Jan 08

EyePoint Inc. to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

GlobeNewswire
·
Jan 07